Suchergebnisse - "Balar, Arjun V"

PubPharm (8)

1

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201) : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Yu, E. | Petrylak, D. | O'Donnell, P. | +17

CommentIn: Lancet Oncol. 2021 Jun;22(6):748-749. - PMID 33991513

2

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

enthalten in: Nature medicine | 2021

von Powles, T. | Carroll, D. | Chowdhury, S. | +21

CommentIn: Nat Med. 2021 May;27(5):761-763. - PMID 33941920

3

Long-Term Outcomes in KEYNOTE-052 : Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Vuky, J. | Balar, A. | Castellano, D. | +13

4

Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer : A Single Institution Experience

enthalten in: Clinical genitourinary cancer | 2020

von Hsu, M. | Xia, Y. | Troxel, A. | +5

5

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Rosenberg, J. | O'Donnell, P. | Balar, A. | +10

CommentIn: J Clin Oncol. 2019 Oct 10;37(29):2587-2591. - PMID 31260641

6

PD-1/PD-L1 Combinations in Advanced Urothelial Cancer : Rationale and Current Clinical Trials

enthalten in: Clinical genitourinary cancer | 2019

von Hsu, M. | Balar, A.

7

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma : a single-arm, multicentre, phase 2 trial

enthalten in: Lancet (London, England) | 2017

von Balar, A. | Galsky, M. | Rosenberg, J. | +33

CommentIn: Lancet. 2017 Jan 7;389(10064):6-7. - PMID 27939401

8

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy : a single-arm, multicentre, phase 2 trial

enthalten in: Lancet (London, England) | 2016

von Rosenberg, J. | Hoffman-Censits, J. | Powles, T. | +28

CommentIn: Lancet. 2016 May 7;387(10031):1881-2. - PMID 26952549

1
[1]